CINECA IRIS Institutional Research Information System

MASTORINO, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.009
EU - Europa 644
AS - Asia 323
AF - Africa 18
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 4
OC - Oceania 1
Totale 2.003
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.006
IT - Italia 397
SG - Singapore 198
IE - Irlanda 85
CN - Cina 61
SE - Svezia 56
IN - India 28
FI - Finlandia 20
FR - Francia 18
NG - Nigeria 16
DE - Germania 14
GB - Regno Unito 14
UA - Ucraina 9
ID - Indonesia 8
JP - Giappone 8
KR - Corea 7
BE - Belgio 5
MY - Malesia 5
NL - Olanda 5
AT - Austria 4
EU - Europa 4
IR - Iran 4
BR - Brasile 3
CA - Canada 3
RO - Romania 3
CI - Costa d'Avorio 2
ES - Italia 2
HR - Croazia 2
PK - Pakistan 2
PL - Polonia 2
SI - Slovenia 2
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GR - Grecia 1
HK - Hong Kong 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
RU - Federazione Russa 1
TR - Turchia 1
Totale 2.003
Salva come PNG Salva come JPEG
Città #
Chandler 287
Singapore 161
Dublin 85
Ashburn 72
Rome 51
Turin 48
Milan 46
Nyköping 45
Princeton 24
Medford 22
Santa Clara 21
New York 20
Lappeenranta 19
Guangzhou 17
Abuja 16
Fairfield 14
Hebei 14
Pune 14
Boston 13
Washington 13
Catania 9
Jakarta 8
Torino 8
Bari 7
Chengdu 7
Florence 7
Beijing 6
Hangzhou 6
Brussels 5
Reggio Emilia 5
Seattle 5
Seoul 5
Wilmington 5
Cambridge 4
Cinisello Balsamo 4
Cittiglio 4
Los Angeles 4
Naples 4
Nellore 4
Norwalk 4
Padova 4
Parma 4
Bologna 3
Castiglione Olona 3
Guiyang 3
Hyderabad 3
London 3
Mountain View 3
Mumbai 3
Porto Empedocle 3
Redmond 3
Urbino 3
Valenzano 3
Woodbridge 3
Abidjan 2
Amsterdam 2
Ancona 2
Antioch 2
Arcole 2
Arezzo 2
Berlin 2
Boardman 2
Brescia 2
Bristol 2
Cesena 2
Cheyenne 2
Esslingen am Neckar 2
Faenza 2
Farra di Soligo 2
Gdansk 2
Genoa 2
Gornji Stupnik 2
Houston 2
Huskvarna 2
Iglesias 2
Karachi 2
Kuala Lumpur 2
Ljubljana 2
L’Aquila 2
Massarosa 2
Modena 2
Mogliano Veneto 2
Molfetta 2
Muggiò 2
Nottingham 2
Novara 2
Perugia 2
Pescara 2
Port Coquitlam 2
Portoferraio 2
Povegliano 2
Purkersdorf 2
Putrajaya 2
Redwood City 2
Salerno 2
San Benedetto del Tronto 2
San Diego 2
San Mauro Pascoli 2
Schwerin 2
Terracina 2
Totale 1.249
Salva come PNG Salva come JPEG
Nome #
Alopecia areata after COVID-19 vaccination 214
Immunotherapy in Xeroderma Pigmentosum: A case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review 77
Immunotherapy in transplanted patients: A special population that can no longer be ignored 70
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era 57
Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration Associated with Merkel Cell Carcinoma with Unknown Primary: A Case Report 57
Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice 54
Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? 54
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients 53
Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study 53
Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma 51
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study 50
Prognostic and predictive biomarkers in stage iii melanoma: Current insights and clinical implications 45
Association between Primary Cutaneous B-cell Lymphomas and Other Skin Cancers: A Multicentre Cohort Study 45
Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related? 45
Dupilumab in HIV-positive patients with atopic dermatitis: A long-term follow-up patient and a literature review 45
Tocilizumab and its usage for skin diseases 44
Ruta graveolens phytophotodermatìtis 42
Misuse, consequences and phototoxic skin-related effects of Rutaceae: a comprehensive literature review 41
Risankizumab shows high efficacy and maintenance in improvement of response until week 52 41
Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real-life study 40
SPECT/CT-Guided Surgical Removal of a Positive External Iliac Sentinel Node in Primary Umbilical Melanoma: Report of a Case, and Up-to-Date Review of the Literature 39
Dupilumab-induced Urticaria 37
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population 37
Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis 32
Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma 30
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy 30
Clinical outcomes and management of JAK inhibitor-associated acne (JAKne) in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study 26
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients 24
Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review 22
593 Inverse psoriasis involvement in moderate to severe psoriatic patients: A comparison between anti IL23 and anti IL17 22
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks 21
Regression of human papillomavirus-associated high-grade vaginal intraepithelial neoplasia after switching from ustekinumab to risankizumab in a psoriasis patient 21
Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata 20
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents 20
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study 19
Dramatic response of face desmoplastic melanoma after two doses of immunotherapy 19
Nonmelanoma skin cancer arising on tattoos 18
Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice? 18
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors 17
Perspectives of immunotherapy in non-melanoma skin cancers 17
A Multicentre, Randomised Clinical Trial to Compare a Topical Nitrizinc® Complex Solution Versus Cryotherapy for the Treatment of Anogenital Warts 17
Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis 16
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement 16
Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report 16
Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study 15
Ocular Surface Disease in Patients With Atopic Dermatitis Treated With Dupilumab: A Prospective Case-Control Study 14
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort 14
Lichen ruber planus arising during dupilumab treatment for atopic dermatitis 14
Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis 14
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis 14
Synchronous occurrence of primary cutaneous B-cell lymphoma and cutaneous Rosai-Dorfman disease in distinct lesions: A unique association 13
Rare scleromyxedema granuloma-annulare-like pattern successfully treated with intravenous immunoglobulins 13
Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience 13
Intraclass Switching among IL17 Inhibitors in Psoriasis: A Real-Life, Long-Term Single-Center Experience 12
Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients 12
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis? 12
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients 12
The Skin Microbiome and Its Role in Psoriasis: A Review 12
A case of treatment-refractory psoriasis as the first manifestation of an HIV-infection 12
Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: Data up to 3 years 12
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study 10
Comparison of response between adults and adolescents in patients with severe atopic dermatitis treated with dupilumab 9
Primary cutaneous lymphoma patients seen at a referral dermatological centre in 1 year: A single-centre observational retrospective cohort study of the diagnoses and staging, comorbidities and associated symptoms, treatment performed and clinical course 9
Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study 9
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study 8
Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study 8
Real-world data on primary cutaneous lymphoproliferative disorders following SARS-CoV-2 vaccination: A multicentre experience from tertiary referral hospitals 8
Exacerbation of acquired perforating dermatosis following SARS-CoV-2 vaccination 8
Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks 8
Drug survival, effectiveness, and safety of brodalumab for moderate‐to‐severe psoriasis over up to 3 years 8
Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis 7
Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis 7
Simultaneous Skin Rejuvenation in Patients Undergoing Medical Treatment for Actinic Keratosis and Non-Melanoma Skin Cancer: A Case Series Analysis 7
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 7
Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies 7
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis 6
The limitation of accessing hospital services due to COVID-19 pandemic: a pilot study of the telephone triage to re-organize the access to a Center for Sexual Health in North-West Italy 6
Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study 6
Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer 6
Long-Term Efficacy and Safety of Dupilumab in Patients with Atopic Dermatitis: A Single-Centre Retrospective Study 5
Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center 5
Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres 5
Response to Letter to the Editor Regarding "A Multicentre, Randomised Clinical Trial to Compare a Topical Nitrizinc® Complex Solution Versus Cryotherapy for the Treatment of Anogenital Warts" 5
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 5
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs 5
Herpes Zoster Infection in Atopic Patients Undergoing Upadacitinib: Practical Suggestions on Vaccination and Management 4
'Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients'-response to Yu et al 4
Maculopapular rash: An overlooked monkeypox diagnostic clue? 4
Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years 4
Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics 3
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 3
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk 3
Reduced doses of biological therapies in psoriasis: a new potentially "sustainable" frontier of psoriasis treatment 3
Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice? 2
Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience 2
Totale 2.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.017
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.017
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 0 2 4
2021/2022311 36 7 6 13 45 17 5 4 10 6 44 118
2022/2023803 55 92 15 58 70 128 36 119 64 18 107 41
2023/2024704 60 104 45 52 33 101 38 43 11 54 45 118
2024/2025322 42 217 63 0 0 0 0 0 0 0 0 0
Totale 2.146